ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Targeting ferroptosis to overcome drug resistance in gastrointestinal cancers.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gastrointestinal cancers, broadly defined to include malignancies arising from the digestive system and associated organs, including gastric, colorectal, pancreatic, and hepatocellular carcinomas, remain among the leading causes of cancer-related mortality worldwide, while the efficacy of conventional therapies continues to be limited by systemic toxicity and acquired resistance. Ferroptosis is an iron-dependent form of regulated cell death characterized by lethal lipid peroxidation and impaired glutathione peroxidase 4 (GPX4)-mediated antioxidant defense. In gastrointestinal cancers, ferroptosis is regulated by the solute carrier family 7 member 11 (SLC7A11)-glutathione (GSH)-GPX4 axis, nuclear factor erythroid 2-related factor 2 (NRF2)-mediated stress adaptation, iron metabolism, and lipid metabolic reprogramming. However, the regulatory landscape and therapeutic potential of ferroptosis across gastrointestinal malignancies remain incompletely understood. In this review, we provide an updated overview of ferroptosis regulation in these cancers, focusing on disrupted iron metabolism, the SLC7A11-GSH-GPX4 antioxidant axis, NRF2-mediated stress adaptation, and lipid metabolic reprogramming. We further discuss emerging evidence regarding ferroptosis-mediated immune modulation, nanotechnology-based therapeutic strategies, and potential biomarkers for patient stratification. Despite encouraging preclinical findings, clinical translation remains hindered by off-target toxicity, insufficient predictive biomarkers, and tumor-context-dependent resistance mechanisms. We propose that ferroptosis-targeted therapies represent a promising adjunctive approach to current treatment modalities; however, successful clinical implementation will require rational combination strategies and biomarker-guided patient selection.
Indexed as
Identifiers
42634063What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.